Moyamoya Disease - A Disease to Count on in Your Daily Practice 2021
DOI: 10.5772/intechopen.95775
|View full text |Cite
|
Sign up to set email alerts
|

Medical Management in Moyamoya Disease

Abstract: Medical treatment seems to be not entirely helpful in the treatment of Moyamoya disease. No evidence supports the benefits of any drug treatment in Moyamoya disease. The ischemic or hemorrhagic event in Moyamoya disease is not preventable with any medical treatment. However, most of the physicians still prescribe the antithrombotic drug for Moyamoya patients with an ischemic event. Moreover, the standard guidelines recommend administering antithrombotic medications to treat Moyamoya with the ischemic event, ev… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 28 publications
0
2
0
Order By: Relevance
“…The rationale for using DAPT is the prevention of thrombogenesis. However, the pathology of ischemic events in MMD may not necessarily have thrombotic etiology hence the controversial role of DAPT [ 17 ]. Antiplatelet and antithrombotic agents can be used as an alternative in the settings of surgical contraindications and for patients before revascularization.…”
Section: Discussionmentioning
confidence: 99%
“…The rationale for using DAPT is the prevention of thrombogenesis. However, the pathology of ischemic events in MMD may not necessarily have thrombotic etiology hence the controversial role of DAPT [ 17 ]. Antiplatelet and antithrombotic agents can be used as an alternative in the settings of surgical contraindications and for patients before revascularization.…”
Section: Discussionmentioning
confidence: 99%
“…In the context of MMD, where hemodynamic impairment is pivotal in brain ischemia[ 15 ], there emerges an ambiguity regarding the degree to which thrombosis contributes to infarction events within this disease profile. Despite this, the potential for thromboembolism with ensuing clot formation in infarction events in MMD necessitates consideration[ 16 ], rendering the role of antithrombotic treatments potentially significant in preemptively addressing infarctions[ 17 ].…”
Section: Antithrombotic Management In MMDmentioning
confidence: 99%